Mogamulizumab-associated rash in CTCL

2 Views
administrator
administrator
08/09/23

Martine Bagot, MD, PhD, Hôpital Saint Louis, Paris, France, discusses one of the main side effects induced by mogamulizumab therapy in patients with cutaneous T-cell lymphoma (CTCL), mogamulizumab-associated rash (MAR). These rashes occur due to reprogramming of the immune system and are clinically and histologically heterogenous. Dr Bagot reports that MAR appears to be associated with better response to treatment and improved prognosis. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

Show more
0 Comments Sort By

    No comments found

    Facebook Comments

    Up next

    CTCL Presentation Varies Widely Among Patients, Even Within Subtypes
    00:02:51
    CTCL Presentation Varies Widely Among Patients, Even Within Subtypes
    administrator
    2 Views
    The Importance of Collaboration in Treating CTCL (Chapter 7)
    00:02:30
    The Importance of Collaboration in Treating CTCL (Chapter 7)
    administrator
    3 Views
    The CTCL diagnosis journey
    00:00:20
    The CTCL diagnosis journey
    administrator
    6 Views
    Unmet needs for late-stage CTCL
    00:01:10
    Unmet needs for late-stage CTCL
    administrator
    3 Views
    Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
    00:01:16
    Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
    administrator
    2 Views
    Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
    00:01:35
    Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
    administrator
    4 Views
    FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay, and Clinical Holds Lifted
    00:08:49
    FDA Approvals in CML, CTCL, CMV Infection, and Tumor Assay, and Clinical Holds Lifted
    administrator
    10 Views
    Pre-clinical activity of tipifarnib in CTCL
    00:02:12
    Pre-clinical activity of tipifarnib in CTCL
    administrator
    5 Views
    Cerdulatinib yields 'encouraging' results in CTCL, PTCL
    00:04:47
    Cerdulatinib yields 'encouraging' results in CTCL, PTCL
    administrator
    3 Views
    CTCL 06 2017
    02:28:08
    CTCL 06 2017
    administrator
    1 Views
    Brentuximab vedotin for CTCL
    00:02:30
    Brentuximab vedotin for CTCL
    administrator
    2 Views
    Clonal evolution in patients with CTCL
    00:02:24
    Clonal evolution in patients with CTCL
    administrator
    3 Views
    RESMAIN: HDAC inhibitor resminostat for CTCL
    00:01:23
    RESMAIN: HDAC inhibitor resminostat for CTCL
    administrator
    1 Views
    Etiopathogenesis of CTCL for dermatology residents I Dr.P.Ram Sushruth
    00:13:18
    Etiopathogenesis of CTCL for dermatology residents I Dr.P.Ram Sushruth
    administrator
    2 Views
    Unmet needs and upcoming therapies in CTCL
    00:03:34
    Unmet needs and upcoming therapies in CTCL
    administrator
    2 Views
    Novel Therapies for CTCL - Andrei Shustov, MD
    01:00:41
    Novel Therapies for CTCL - Andrei Shustov, MD
    administrator
    3 Views
    Miles Prince, MD, on the concerns when choosing a treatment plan for newly diagnosed CTCL patients
    00:01:02
    Miles Prince, MD, on the concerns when choosing a treatment plan for newly diagnosed CTCL patients
    administrator
    4 Views
    Unmet needs and upcoming therapies in CTCL
    00:03:34
    Unmet needs and upcoming therapies in CTCL
    administrator
    3 Views
    Living with CTCL
    00:00:52
    Living with CTCL
    administrator
    2 Views